Human Pathology
Volume 40, Issue 12 , Pages 1754-1761 , December 2009

Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers

  • Michael C. Haffner, MD

      Affiliations

    • Division of Medical Biochemistry, Biocenter, Innsbruck Medical University, A-6020 Innsbruck, Austria
    • Department of Urology, Weill Medical College of Cornell University, New York, NY 10065, USA
    • Corresponding Author InformationCorresponding author. Division of Medical Biochemistry, Biocenter, Innsbruck Medical University, A-6020 Innsbruck, Austria.
    • MCH and IEK contributed equally to this work.
    • ,
  • Irmgard E. Kronberger, MD

      Affiliations

    • Department of General and Transplant Surgery, Innsbruck Medical University, A-6020 Innsbruck, Austria
    • MCH and IEK contributed equally to this work.
    • ,
  • Jeffrey S. Ross, MD

      Affiliations

    • Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York 12208, USA
    • ,
  • Christine E. Sheehan, MD

      Affiliations

    • Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York 12208, USA
    • ,
  • Matthias Zitt, MD

      Affiliations

    • Department of General and Transplant Surgery, Innsbruck Medical University, A-6020 Innsbruck, Austria
    • ,
  • Gilbert Mühlmann, MD

      Affiliations

    • Department of General and Transplant Surgery, Innsbruck Medical University, A-6020 Innsbruck, Austria
    • ,
  • Dietmar Öfner, MD

      Affiliations

    • Department of General and Transplant Surgery, Innsbruck Medical University, A-6020 Innsbruck, Austria
    • ,
  • Bettina Zelger, MD

      Affiliations

    • Department of Pathology, Innsbruck Medical University, A-6020 Innsbruck, Austria
    • ,
  • Christian Ensinger, MD

      Affiliations

    • Department of Pathology, Innsbruck Medical University, A-6020 Innsbruck, Austria
    • ,
  • Ximing J. Yang, MD, PhD

      Affiliations

    • Department of Pathology and Laboratory Medicine, New York-Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY 10021, USA
    • ,
  • Stephan Geley, MD

      Affiliations

    • Division of Molecular Pathophysiology, Biocenter, Innsbruck Medical University, A-6020 Innsbruck, Austria
    • ,
  • Raimund Margreiter, MD

      Affiliations

    • Department of General and Transplant Surgery, Innsbruck Medical University, A-6020 Innsbruck, Austria
    • ,
  • Neil H. Bander, MD

      Affiliations

    • Department of Urology, Weill Medical College of Cornell University, New York, NY 10065, USA

Received 1 March 2009 ,Revised 6 June 2009 ,Accepted 11 June 2009.

References 

  1. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer. 2005;5:436–446
  2. St Croix B, Rago C, Velculescu V, et al. Genes expressed in human tumor endothelium. Science. 2000;289:1197–1202
  3. Seaman S, Stevens J, Yang MY, Logsdon D, Graff-Cherry C, St Croix B. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell. 2007;11:539–554
  4. Rajasekaran AK, Anilkumar G, Christiansen JJ. Is prostate-specific membrane antigen a multifunctional protein?. Am J Physiol Cell Physiol. 2005;288:C975–C981
  5. Ross JS, Sheehan CE, Fisher HA, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res. 2003;9:6357–6362
  6. Perner S, Hofer MD, Kim R, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol. 2007;38:696–701
  7. Davis MI, Bennett MJ, Thomas LM, Bjorkman PJ. Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc Natl Acad Sci U S A. 2005;102:5981–5986
  8. Aggarwal S, Singh P, Topaloglu O, Isaacs JT, Denmeade SR. A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity. Cancer Res. 2006;66:9171–9177
  9. Foss CA, Mease RC, Fan H, et al. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res. 2005;11:4022–4028
  10. Lupold SE, Hicke BJ, Lin Y, Coffey DS. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res. 2002;62:4029–4033
  11. Slovin SF. Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen. Expert Opin Ther Targets. 2005;9:561–570
  12. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of [177]lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol. 2005;23:4591–4601
  13. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol. 2004;22:2522–2531
  14. Liu H, Moy P, Kim S, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 1997;57:3629–3634
  15. Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res. 1999;5:2674–2681
  16. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81–85
  17. Milowsky MI, Nanus DM, Kostakoglu L, et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol. 2007;25:540–547
  18. Morris MJ, Pandit-Taskar N, Divgi CR, et al. Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors. Clin Cancer Res. 2007;13:2707–2713
  19. Folkman J. Angiogenesis. Annu Rev Med. 2006;57:1–18
  20. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2002;2:727–739
  21. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342
  22. Mhawech-Fauceglia P, Zhang S, Terracciano L, et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using multiple tumour tissue microarray technique. Histopathology. 2007;50:472–483
  23. Kinoshita Y, Kuratsukuri K, Landas S, et al. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg. 2006;30:628–636
  24. Baccala A, Sercia L, Li J, Heston W, Zhou M. Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology. 2007;70:385–390
  25. Al-Ahmadie HA, Olgac S, Gregor PD, et al. Expression of prostate-specific membrane antigen in renal cortical tumors. Mod Pathol. 2008;21:727–732
  26. Gordon IO, Tretiakova MS, Noffsinger AE, Hart J, Reuter VE, Al-Ahmadie HA. Prostate-specific membrane antigen expression in regeneration and repair. Mod Pathol. 2008;
  27. Conway RE, Petrovic N, Li Z, Heston W, Wu D, Shapiro LH. Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol. 2006;26:5310–5324
  28. Bander NH, Nanus DM, Milowsky MI, Kostakoglu L, Vallabahajosula S, Goldsmith SJ. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol. 2003;30:667–676
  29. Zhou J, Neale JH, Pomper MG, Kozikowski AP. NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat Rev Drug Discov. 2005;4:1015–1026
  30. Galsky MD, Eisenberger M, Moore-Cooper S, et al. Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol. 2008;26:2147–2154

☆ Supported by the David H. Koch Foundation.

PII: S0046-8177(09)00207-X

doi: 10.1016/j.humpath.2009.06.003

Human Pathology
Volume 40, Issue 12 , Pages 1754-1761 , December 2009

Article Tools

* Image Usage & Resolution